Sanofi comments on Medivation’s rejection

Sanofi SA said it would solicit Medivation Inc’s shareholders directly after the US biotech’s board of directors unanimously rejected the French company’s unsolicited takeover bid of $52.50 per share as substantially undervaluing the company.